Purpose of ReviewAntibody-drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023.Recent FindingsWe hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach.SummaryThis review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review / Mathiot, Laurent; Baldini, Capucine; Letissier, Octave; Hollebecque, Antoine; Bahleda, Rastislav; Gazzah, Anas; Smolenschi, Cristina; Sakkal, Madona; Danlos, François-Xavier; Henon, Clémence; Beshiri, Kristi; Goldschmidt, Vincent; Parisi, Claudia; Patrikidou, Anna; Michot, Jean-Marie; Marabelle, Aurélien; Postel-Vinay, Sophie; Bernard-Tessier, Alice; Loriot, Yohann; Ponce, Santiago; Champiat, Stéphane; Ouali, Kaïssa. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - 26:10(2024). [10.1007/s11912-024-01576-9]
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review
Parisi, ClaudiaValidation
;
2024
Abstract
Purpose of ReviewAntibody-drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023.Recent FindingsWe hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach.SummaryThis review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
